Engineers Gate Manager LP Vir Biotechnology, Inc. Transaction History

Engineers Gate Manager LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.63 - $12.66 $17,075 - $28,333	2,238 Added 4.86%	48,294 $429,000
Q1 2024 May 15, 2024	SELL	$8.6 - $11.9 $262,437 - $363,140	-30,516 Reduced 39.85%	46,056 $466,000
Q4 2023 Feb 14, 2024	BUY	$7.76 - $10.29 $459,182 - $608,890	59,173 Added 340.09%	76,572 $770,000
Q3 2023 Nov 14, 2023	BUY	$9.14 - $24.62 $159,026 - $428,363	17,399 New	17,399 $163,000
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $971,470 - $1.35 Million	43,642 Added 232.16%	62,440 $1.45 Million
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $826,902 - $1.17 Million	-41,428 Reduced 68.79%	18,798 $475,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $327,986 - $558,618	17,962 Added 42.5%	60,226 $1.16 Million
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $123,466 - $172,775	-6,471 Reduced 13.28%	42,264 $1.08 Million
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $1.03 Million - $1.95 Million	48,735 New	48,735 $1.25 Million
Q4 2021 Feb 14, 2022	SELL	$30.97 - $54.03 $1.05 Million - $1.83 Million	-33,864 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $1.18 Million - $1.85 Million	33,864 New	33,864 $1.47 Million

215

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.41B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.